Multiple Implications of 3-phosphoinositide-dependent Protein Kinase 1 in Human Cancer

Overview

Journal World J Biol Chem

Publisher Baishideng Publishing Group

Specialty Biochemistry

Date 2011 May 4

PMID 21537480

Citations 10

Authors

Yuwen Li

Keum-Jin Yang

Jongsun Park

Affiliations

Soon will be listed here.

Abstract

3-phosphoinositide-dependent protein kinase-1 (PDK1) is a central mediator of cellular signaling between phosphoinositide-3 kinase and various intracellular serine/threonine kinases, including protein kinase B, p70 ribosomal S6 kinase, serum and glucocorticoid-inducible kinase, and protein kinase C. PDK1 activates members of the AGC family of protein kinases by phosphorylating serine/threonine residues in the activation loop. Here, we review the regulatory mechanisms of PDK1 and its roles in cancer. PDK1 is activated by autophosphorylation in the activation loop and other serine residues, as well as by phosphorylation of Tyr-9 and Tyr-373/376. Src appears to recognize PDK1 following tyrosine phosphorylation. The role of heat shock protein 90 in regulating PDK1 stability and PDK1-Src complex formation are also discussed. Furthermore, we summarize the subcellular distribution of PDK1. Finally, an important role for PDK1 in cancer chemotherapy is proposed. In conclusion, a better understanding of its molecular regulatory mechanisms in various signaling pathways will help to explain how PDK1 acts as an oncogenic kinase in various cancers, and will contribute to the development of novel cancer chemotherapies.

Citing Articles

Plant-derived cell-penetrating microprotein α-astratide aM1 targets Akt signaling and alleviates insulin resistance.

Dutta B, Loo S, Kam A, Tam J Cell Mol Life Sci. 2023; 80(10):293.

PMID: 37715850 PMC: 10505102. DOI: 10.1007/s00018-023-04937-y.

The Cellular Prion Protein-ROCK Connection: Contribution to Neuronal Homeostasis and Neurodegenerative Diseases.

Schneider B, Baudry A, Pietri M, Alleaume-Butaux A, Bizingre C, Nioche P Front Cell Neurosci. 2021; 15:660683.

PMID: 33912016 PMC: 8072021. DOI: 10.3389/fncel.2021.660683.

Defective insulin signaling and the protective effects of dimethyldiguanide during follicular development in the ovaries of polycystic ovary syndrome.

Wang F, Wang S, Zhang Z, Lin Q, Liu Y, Xiao Y Mol Med Rep. 2017; 16(6):8164-8170.

PMID: 28990055 PMC: 5779901. DOI: 10.3892/mmr.2017.7678.

Spatial control of translation repression and polarized growth by conserved NDR kinase Orb6 and RNA-binding protein Sts5.

Nunez I, Pino M, Wiley D, Das M, Chen C, Goshima T Elife. 2016; 5.

PMID: 27474797 PMC: 5011436. DOI: 10.7554/eLife.14216.

The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction.

Oudart J, Doue M, Vautrin A, Brassart B, Sellier C, Dupont-Deshorgue A Oncotarget. 2015; 7(2):1516-28.

PMID: 26621838 PMC: 4811477. DOI: 10.18632/oncotarget.6399.

References

Xie Z, Yuan H, Yin Y, Zeng X, Bai R, Glazer R . 3-phosphoinositide-dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases. BMC Cancer. 2006; 6:77. PMC: 1459872. DOI: 10.1186/1471-2407-6-77. View

Kikani C, Dong L, Liu F . "New"-clear functions of PDK1: beyond a master kinase in the cytosol?. J Cell Biochem. 2005; 96(6):1157-62. DOI: 10.1002/jcb.20651. View

Lu Z, Cox-Hipkin M, Windsor W, Boyapati A . 3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway. Mol Cancer Res. 2010; 8(3):421-32. DOI: 10.1158/1541-7786.MCR-09-0179. View

Bayascas J, Leslie N, Parsons R, Fleming S, Alessi D . Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol. 2005; 15(20):1839-46. DOI: 10.1016/j.cub.2005.08.066. View

Carnero A . The PKB/AKT pathway in cancer. Curr Pharm Des. 2010; 16(1):34-44. DOI: 10.2174/138161210789941865. View

Wick M, Ramos F, Chen H, Quon M, Dong L, Liu F . Mouse 3-phosphoinositide-dependent protein kinase-1 undergoes dimerization and trans-phosphorylation in the activation loop. J Biol Chem. 2003; 278(44):42913-9. DOI: 10.1074/jbc.M304172200. View

Al-Ali H, Ragan T, Gao X, Harris T . Reconstitution of modular PDK1 functions on trans-splicing of the regulatory PH and catalytic kinase domains. Bioconjug Chem. 2007; 18(4):1294-302. PMC: 2525508. DOI: 10.1021/bc070055r. View

Jung H, Kim D, Jo Y, Chung H, Song J, Park J . Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol Endocrinol. 2005; 19(11):2748-59. DOI: 10.1210/me.2005-0122. View

Chun J, Kwon T, Lee E, Hyun S, Hong S, Kang S . The subcellular localization of 3-phosphoinositide-dependent protein kinase is controlled by caveolin-1 binding. Biochem Biophys Res Commun. 2004; 326(1):136-46. DOI: 10.1016/j.bbrc.2004.10.208. View

10.

McManus E, Collins B, Ashby P, Prescott A, Murray-Tait V, Armit L . The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J. 2004; 23(10):2071-82. PMC: 424399. DOI: 10.1038/sj.emboj.7600218. View

11.

Feldman R, Wu J, Polokoff M, Kochanny M, Dinter H, Zhu D . Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005; 280(20):19867-74. DOI: 10.1074/jbc.M501367200. View

12.

Koziak K, Kaczmarek E, Park S, Fu Y, Avraham S, Avraham H . RAFTK/Pyk2 involvement in platelet activation is mediated by phosphoinositide 3-kinase. Br J Haematol. 2001; 114(1):134-40. DOI: 10.1046/j.1365-2141.2001.02894.x. View

13.

Bozulic L, Hemmings B . PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol. 2009; 21(2):256-61. DOI: 10.1016/j.ceb.2009.02.002. View

14.

Summy J, Qian Y, Jiang B, Guappone-Koay A, Gatesman A, Shi X . The SH4-Unique-SH3-SH2 domains dictate specificity in signaling that differentiate c-Yes from c-Src. J Cell Sci. 2003; 116(Pt 12):2585-98. DOI: 10.1242/jcs.00466. View

15.

Peifer C, Alessi D . New anti-cancer role for PDK1 inhibitors: preventing resistance to tamoxifen. Biochem J. 2008; 417(1):e5-7. DOI: 10.1042/BJ20082243. View

16.

Alessi D, Deak M, Casamayor A, Caudwell F, Morrice N, Norman D . 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol. 1997; 7(10):776-89. DOI: 10.1016/s0960-9822(06)00336-8. View

17.

Bayascas J, Wullschleger S, Sakamoto K, Garcia-Martinez J, Clacher C, Komander D . Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol. 2008; 28(10):3258-72. PMC: 2423167. DOI: 10.1128/MCB.02032-07. View

18.

Pearce L, Komander D, Alessi D . The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol. 2009; 11(1):9-22. DOI: 10.1038/nrm2822. View

19.

Baryawno N, Sveinbjornsson B, Eksborg S, Chen C, Kogner P, Johnsen J . Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res. 2009; 70(1):266-76. DOI: 10.1158/0008-5472.CAN-09-0578. View

20.

Falasca M, Logan S, Lehto V, Baccante G, Lemmon M, Schlessinger J . Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J. 1998; 17(2):414-22. PMC: 1170392. DOI: 10.1093/emboj/17.2.414. View